550
Participants
Start Date
November 9, 2018
Primary Completion Date
August 31, 2027
Study Completion Date
August 31, 2027
ZYN002 - Cannabidiol Transdermal Gel
Pharmaceutically manufactured. Cannabidiol formulated as a clear gel (transdermal delivery)
Westmead Children's Hospital, Sydney
Genetics Clinics Australia, Melbourne
Lady Cilento Children's Hospital - South Brisbane, Brisbane
Wellington Hospital, Wellington
The Fragile X Spectrum Disorder Clinic at Icahn School of Medicine at Mount Sinai, Division of Medical Genetics, New York
Penn State Milton S. Hershey Medical Center, Hershey
Children's Research Institute, Washington D.C.
Kennedy Krieger Institute, Baltimore
Greenwood Genetic Center, Greenville
Han Phan, Atlanta
University of Miami, Miami
University of Mississipi Medical Center, Jackson
Cincinnati Children's Hospital Medical Center, Cincinnati
Masonic Institute of Developing Brain, Minneapolis
Rush University Medical Center, Chicago
Central States Research, Tulsa
Children's Hospital of Colorado, Denver
Primary Children's Hospital, Salt Lake City
Southwest Autism Research and Resource Center, Phoenix
Science 37, Culver City
Amnova Clinical Research, LLC, Irvine
UC Davis Health System, MIND Institute, Sacramento
Boston Children's Hospital, Boston
Research Space, Leicester
Children's Clinical Research Facility, Royal Hospital for Children and Young People, Edinburgh
Manchester University NHS Foundation Trust, Manchester
Zynerba Pharmaceuticals, Inc.
INDUSTRY